摘要
目的评价吉西他滨联合顺铂治疗治疗膀胱癌临床疗效及安全性研究。方法入选2012年10月~2015年8月入住浙江省肿瘤医院的92例膀胱癌患者。采用随机数字表法将患者分为观察组和对照组,每组46例。在常规营养支持和对症治疗的基础上,第1~3天对照组共静脉滴注顺铂70 mg/m^2,观察组在此基础上第1天、8天联合吉西他滨1 000 mg/m^2静脉滴注,21 d为1个疗程,连续治疗2个疗程。比较2组临床疗效、白介素17（IL-17）、白介素18（IL-18）、血转化生长因子-β（TGF-β）、血管内皮生长因子（VEGF）以及尿TGF-β1水平和不良反应发生情况。结果治疗后对照组临床总有效率（63.05%）显著低于观察组（76.09%）（P〈0.05）。治疗后2组血清IL-17、IL-18、TGF-β1及VEGF水平均显著降低,且观察组显著低于对照组（P〈0.05）;尿TGF-β1水平显著上升,且组间比较存在显著性差异（P〈0.05）。对照组和观察组不良反应发生率分别为15.22%和6.52%,比较差异无统计学意义。结论吉西他滨联合顺铂治疗膀胱癌临床疗效显著,安全性较高。
Objective To evaluate the clinical efficacy and safety of gemcitabine combined with cisplatin in the treatment of bladder cancer.MethodsFrom October 2012 to August 2015, 92 patients with bladder cancer were enrolled in our hospital.Patients were divided into observation group and control group by random number table method.On the basis of routine nutrition support and symptomatic treatment, cisplatin was administered by intravenous infusion of cisplatin 70mg/m2 in the first 3d in control group.On the 1d and 8d, gemcitabine 1000mg/m2 was intravenously infused in observation group and 21 days treatment was taken continuous for 2 courses.Curative effect, IL-17, IL-18, transforming growth factor-β （TGF-β）, vascular endothelial growth factor （VEGF） and urinary TGF-β1 levels and adverse reactions of two groups were comparatively studied.ResultsThe total effective rate in the control group （63.05%） was significantly lower than that in the observation group （76.09%） （P〈0.05）.After treatment, the levels of serum IL-17, IL-18, TGF-β1 and VEGF in the two groups were significantly decreased and with significant difference between two groups （P〈0.05）.The levels of urinary TGF-β1 were significantly increased and with significant difference between two groups （P〈0.05）.The incidence of adverse reactions in the control and observation groups was 15.22% and 6.52%, respectively.There was no significant difference between the two groups.ConclusionGemcitabine combined with cisplatin has a significant clinical efficacy and safety in the treatment of bladder cancer.
出处
《中国生化药物杂志》
CAS
2017年第5期316-317,320,共3页
Chinese Journal of Biochemical Pharmaceutics
关键词
吉西他滨
顺铂
膀胱癌
临床疗效
安全性
gemcitabine
cisplatin
bladder cancer
clinical efficacy
safety
